Structure-activity and structure-side-effect relationships for the quinolone antibacterials

Journal of Antimicrobial Chemotherapy

Volumn 33, Issue 4, 1994, Pages 685-706

  Domagala, John M ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORINE; CYCLOPROPANE DERIVATIVE; FLUORINE; NONSTEROID ANTIINFLAMMATORY AGENT; PIPERAZINE; PYRROLIDINE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THEOPHYLLINE;

ALKYLATION; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ARTHROPATHY; CENTRAL NERVOUS SYSTEM DISEASE; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; GENOTOXICITY; GRAM POSITIVE BACTERIUM; PHOTOTOXICITY; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMAL; ANTI-INFECTIVE AGENTS, QUINOLONE; BACTERIA; HUMAN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0028316927     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/33.4.685     Document Type: Review

References (72)

1. Akahane, K., Sekiguchi, M., Une, T. and Osada, Y. (1989). Structure-epileptogenicity relationship of quinolones with special reference to their interaction with y-aminobutyric acid receptor sites. Antimicrobial Agents and Chemotherapy 33, 1704-8.
2. Anon (1992). AM-1091, Clinafloxacin, PD 127391, Bay-v-3545, CI-960. Drugs of the Future 17, 938-9.
3. Asahina, Y., Ishizaki, T. and Suzue, S. (1992). Recent advances in structure-activity relationships in new quinolones. In Fluorinated Quinolones New Quinolone Antimicrobials (Mitsuhashi, S., Ed). Progress in Drug Research, Vol. 38 (Junker, E., Ed), pp. 57-106. Birkhauser Verlag, Basle.
4. Bergan, T., Rohwedder, R. and Thorsteinsson, S. B. (1989). Significance of crystalluria caused by quinolones. Reviews of Infectious Diseases 11, Suppl. 5, SI395-6.
5. Chapman, J. S. and Georgopapadakou, N. H. (1988). Routes to quinolone permeation in Escherichia coli. Antimicrobial Agents and Chemotherapy 32, 438-42.
6. Chevalier, X., Albengres, E., Voisin, M. C., Tillement, J. P. and Larget-Piet, B. (1992). A case of destructive polyarthropathy in a 17-year old youth following pefloxacin treatment. Drug Safety 7, 310-4.
7. Chu, D. T. W. (1992). Isothiazoloquinolones: antibacterial and antineoplastic agents. Drugs of the Future 17, 1101-9.
8. Chu, D. T. W. and Fernandes, P. B. (1991). Recent developments in the field of quinolone antibacterial agents. In Advances in Drug Research, Vol. 21 (Testa, B., Ed.), pp. 39-144. Academic Press, New York.
9. Ciaravino, V., Suto, M. J. and Theiss, J. C. (1993). High capacity in vitro micronucleus assay for the assessment of chromosome damage: results with quinolone/naphthyridine antibacterials. Mutation Research 298, 227-36.
10. Crumplin, G. C. (1990). In-vitro genotoxicity assessment and the effects of 4-quinolones upon human cells. In The 4-Quinolones: Antibacterial Agents In Vitro (Crumplin, G. C., Ed.), pp. 174-200, Springer Verlag, London.
11. Domagala, J. M., Hagen, S. E., Joannides, T., Kiely, J. S., Laborde, E., Schroeder, M. C. et al. (1993). Quinolone antibacterials containing the new 7-3-(l-aminoethyl)-l-pyrrohdinyl side chain: the effects of the 1-aminoethyl moiety and its stereochemical configurations on potency and in-vivo efficacy. Journal of Medicinal Chemistry 36, 871-82.
12. Domagala, J. M., Bridges, A. J., Culbertson, T. P., Gambino, L., Hagen, S. E., Karrick, G. et al. (1991). Synthesis and biological activity of 5-amino and 5-hydroxyquinolones, and the overwhelming influence of the remote N,-substituent in determining the structure-activity relationship. Journal of Medicinal Chemistry 34, 1142-54.
13. Finch, R. G. (1993). The withdrawal of temafloxacin. Are there implications for other quinolones. Drug Safety 8, 9-11.
14. Foote, C. S. (1976). Photosensitized oxidation and singlet oxygen: consequences in biological systems. In Free Radicals in Biology (Pryor, W. A., Ed.), pp. 85-133. Academic Press, New York.
15. Forsgren, A., Bredberg, A. and Riesbeck, K. (1989). New quinolones: in-vitro effects as a potential source of clinical toxicity. Reviews of Infectious Diseases 11, Suppl. 5, SI 382-9.
16. Fuhr, U., Anders, E., Mahr, G., Sorgel, F. and Staib, A. H. (1992). Inhibitory potency of quinolone antibacterial agents against cytochrome P450 IA2 activity in vivo and in vitro. Antimicrobial Agents and Chemotherapy 36, 942-8.
17. Fuhr, U., Strobl, G., Manaut, F., Anders, E., Sorgel, F., Lopez-de-Brines, E. et al. (1993). Quinolone antibacterial agents: relationship between structure and in-vitro inhibition of human cytochrome P-450 isoform CYP1A2. Molecular Pharmacology 43, 191-9.
18. Gootz, T. D., Barrett, J. F. and Sutcliffe, J. A. (1990). Inhibitory effects of quinolone antibacterial agents on eucaryotic topoisomerases and related test systems. Antimicrobial Agents and Chemotherapy 34, 8-12.
19. Gough, A. W., Kasali, O. B., Sigler, R. E. and Baragi, V. (1992). Quinolone arthropathyacute toxicity to immature articular cartilage. Toxicologic Pathology 20, 436-50.
20. Gracheck, S. J., Mychajlonka, M., Gambino, L., Cohen, M. A., Roland, G., Ciaravino, V. et al. (1991). Correlations of quinolone inhibition endpoints vs bacterial DNA gyrase, mammalian topoisomerase I and II and cell clonogenic survival, and in-vitro micronucleus induction. In Program and Abstracts of the Thirty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1991. Abstract 1488. American Society for Microbiology, Washington, DC.
21. Hagen, S., Domagala, J. M., Heifetz, C., Sanchez, J., Sesnie, J., Stier, M. et al. (1991). Synthesis and antibacterial activity of new 7-3-(l -amino- l-methylethyl)-l-pyrrolidinyl-4-quinolones. In Program and Abstracts of the Thirty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1991. Abstract 1438. American Society for Microbiology Washington, DC.
22. Halliwell, R. F., Davey, P. G. and Lambert, J. J. (1993). Antagonism of GABAa receptors by 4-quinolones. Journal Antimicrobial Chemotherapy 31, 457-62.
23. Hasegawa, T., Nadai, M., Kuzuya, T., Muraoka, I., Apichartpichean, R. Takagi, K. el al., (1990). The possible mechanism of interaction between xanthines and quinolones. Journal of Pharmaceutical Pharmacology 42, 767-72.
24. Hori, S., Kanemitsu, K. and Shimada, J. (1992). Inhibitory activity of AM 1155 on y-aminobutyric acid receptor binding. A comparative study on convulsant activity of new quinolones. In Program and Abstracts of the Thirty-Second Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, 1992. Abstract 1000. American Society for Microbiology Washington, DC.
25. Hori, S., Shimada, J., Sakai, O. and Matsuda, M. (1991). Effect of OPC 17116 a newly synthesized quinolone on y-aminobutyric acid receptor binding: a comparative study of epileptogenic activity of quinolones. In Program and Abstracts of the Thirty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1991. Abstract 1480. American Society for Microbiology, Washington, DC.
26. Hoshino, K., Sato, K., Une, T. and Osada, Y. (1989). Inhibitory effects of quinolones on DNA gyrase of Escherichia coli and topoisomerase II of fetal calf thymus. Antimicrobial Agents and Chemotherapy 33, 1816-8.
27. Hoshino, K., Hayakawa, I., Sato, K., Sato, M., Kitamura, A. and Osada, Y. (1991). Inhibitory effects of DU 6859, a new fluoroquinolone on bacterial DNA gyrase and topoisomerase II. In Program and Abstracts of the Thirty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1991. Abstract 1506. American Society for Microbiology, Washington, DC.
28. Ikeda, Y., Iwao, E., Yokoyama, Y., Araki, K., Yakushiji, T. and Takamatsu, R. (1990). Tissue distribution and drug interactions of Y-26611 a novel quinolone in mice and rats. In Program and Abstracts of the Thirtieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, 1990. Abstract 391. American Society for Microbiology, Washington, DC.
29. Ito, T., Otsuki, M. and Nishino, T. (1992). In-vitro antibacterial activity of Q-35, a new fluoroquinolone. Antimicrobial Agents and Chemotherapy 36, 1708-14.
30. Janknegt, R. (1990). Drug interactions with quinolones. Journal of Antimicrobial Chemotherapy 26, Suppl. D, 7-29.
31. Janknegt, R. and Hekster, Y. A. (1989). Developments in quinolones. Pharmaceutisch Weekblad Scientific Edition 11, 33-43.
32. Kimura, M., Niki, Y., Nakabayashi, M., Nakahama, C. and Soejima, R. (1991). The effect of Y-26611 on serum concentration of theophylline. In Program and Abstracts of the Thirty-First interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1991. Abstract 1503. American Society for Microbiology, Washington, DC.
33. Komatsu, Y., Yoshida, S. and Mitsuhashi, S. (1991). Antibacterial activity of Y-26611, a new quinolone. In Program and Abstracts of the Thirty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1991. Abstract 1500. American Society for Microbiology, Washington, DC
34. Lomaestro, B. M. and Bailie, G. R. (1991). Quinolonecation interactions: a review. DICP, The Annals of Pharmacotherapy 25, 1249-58.
35. Marshall, S. A. and Jones, R. N. (1993). In vitro activity of DU 6859a, a new fluorocyclopropyl quinolone. Antimicrobial Agents and Chemotherapy 37, 2747-53.
36. Matsumoto, M., Kajima, K., Nagano, H., Matsubara, S. and Yokota, T. (1992). Photostability and biological activity of fluoroquinolones substituted at the 8-position after UV irradiation. Antimicrobial Agents and Chemotherapy 36, 1715-9.
37. Mitelman, F., Kolnig, A., Strombeck, B., Norrby, R., Kromann-Andersen, B., Sommer, P. et al. (1988). No cytogenetic effects of quinolone treatment in humans. Antimicrobial Agents and Chemotherapy 32, 936-7.
38. Mitsuhashi, S. (Ed). (1992). Fluorinated quinolones new quinolone antimicrobials. In Progress in Drug Research, Vol. 38 (Junker, E., Ed.), pp. 9-148. Birkhauser Verlag, Basle.
39. Moreau, N. J., Robaux, H., Baron, L. and Tabary, X. (1990). Inhibitory effects of quinolones on pro and eucaryotic DNA topoisomerases I and II. Antimicrobial Agents and Chemotherapy 34, 1955-60.
40. Niki, Y., Hashiguchi, K., Okimoto, N. and Soejima, R. (1992). Quinolone antimicrobial agents and theophylline. Chest 101, 881.
41. Norrby, S. R. (1991). Side effects of quinolones: comparisons between quinolones and other antibiotics. European Journal of Clinical Microbiology and Infectious Disease 10, 378-83.
42. Oomori, Y., Yasue, T., Aoyama, H., Hirai, K., Suzue, S. and Yokota, T. (1988). Effects of fleroxacin on HeLa cell functions and topoisomerase II. Journal of Antimicrobial Chemotherapy 22, Suppl. D, 91-7.
43. Osheroff, N., Elsea, S. H. and Nitiss, J. L., (1992a). Cytotoxicity of quinolones toward eukaryotic cells. Journal of Biological Chemistry 267, 13150-3.
44. Osheroff, N., Robinson, M. J., Martin, B. A., Gootz, T. D. and McGuirk, P. R. (1992b). Effects of novel quinolones on the catalytic activities of eukaryotic topoisomerase II: influence of the Cj-fluorine groups. Antimicrobial Agents and Chemotherapy 36, 751-6.
45. Paton, J. H. and Reeves, D. S. (1991). Clinical features and management of adverse effects of quinolone antibacterials. Drug Safety 6, 8-27.
46. Paton, D. H. and Reeves, D. S. (1992). Adverse reactions to the fluoroquinolones. Adverse Drug Reaction Bulletin 153, 575-8.
47. Percival, A. (1991). Impact of the chemical structure on quinolone potency, spectrum, and side effects. Journal of Antimicrobial Chemotherapy 28, Suppl. C, 1-8.
48. Prince, R. A. (1989). Fluoroquinolone drug interactions: an overview. Antimicrobic Newsletter, 6, 93-8.
49. Remuzon, P., Bouzard, D., Guiol, C. and Jacquet, J. (1992). Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationship of new chiral 7-(l-,3-,4-, and 6-methyl-2,5-diazabicyclo2.2.1heptan-2-yl)naphthyridine analogues of 7-(lR, 4R)-2,5- diazabicyclo2.2.1 jheptan- 2-yl-1 -(1,1 -dimethylethyl)-6-fluoro- 1,4-dihydro-4-oxo-1,8-naph- thyridine-3-carboxylic acid. Influence of the configuration on blood pressure in dogs. A quinolone-class effect. Journal of Medicinal Chemistry 35, 2898-909.
50. Robertson, D. G., Epling, G. A., Kiely, J. S., Bailey, D. L. and Song, B. (1991). Mechanistic studies on the phototoxic potential of PD 117596, a quinolone antibacterial compound. Toxicology and Applied Pharmacology 111, 221-32.
51. Rosen, T., Chu, D. T. W., Lico, I. M., Fernandes, P. B., Marsh, K., Shen, L. et al. (1988). Design, synthesis, and properties of (4S)-7-(4-amino-2-substituted-pyrrolinyl) quinolone-3- carboxylic acids. Journal of Medicinal Chemistry 31, 1598-611.
52. Ross, D. L., Elkinton, S. K. and Riley, C. M. (1992). Physiochemical properties of the fluoroquinolone antimicrobials. III. Octanol water partition coefficients and their relationship to structure. International Journal of Pharmaceutics 88, 379-89.
53. Sanchez, J. P., Bridges, A. J., Busch, R., Domagala, J. M., Gogliotti, R. D., Hagen, S. E. et al. (1992). New 8-(trifluoromethyl) substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk. Journal of Medicinal Chemistry 35, 361-7.
54. Sanchez, J. P., Domagala, J. M., Hagen, S. E., Heifetz, C. L., Hutt, M. P., Nichols, J. B. et al. (1988). Quinolone antibacterial agents. Synthesis and structure-activity relationships of 8- substituted quinolone-3-carboxylic acids. Journal of Medicinal Chemistry 31, 983-91.
55. Sarkar, M., Polk, R. E., Gruzelian, P. S., Hunt, C. and Karnes, H. T. (1990). In-vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes. Antimicrobial Agents and Chemotherapy 34, 594-9.
56. Schaad, U. B. (1992). The role of the new quinolones in pediatric practice. Pediatric Infectious Disease Journal 11, 1043-6.
57. Schaad, U. B., Sander, E., Wedgewood, J. and Schaffner, T. (1992). Morphological studies for skeletal toxicity after prolonged ciprofloxacin therapy in two juvenile cystic fibrosis patients. Pediatric Infectious Disease Journal 11, 1047-9.
58. Schluter, G. (1989). Ciprofloxacin: toxicologic evaluation of additional safety data. American Journal of Medicine 87, Suppl. 5A, 37S.
59. Segev, S., Rehavi, M. and Rubinstein, E. (1988). Quinolones, theophylline, and diclofenac interactions with the y-aminobutyric acid receptor. Antimicrobial Agents and Chemotherapy 32, 1624-6.
60. Sesnie, J. C., Heifetz, C. L., Joannides, E. T., Malta, T. E. and Shapiro, M. A. (1990). Comparative phototoxicity of quinolones in a mouse phototolerance model. In Program and Abstracts of the Thirtieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, 1990. Abstract 399. American Society for Microbiology, Washington, DC.
61. Shentag, J. J. and Nix, D. E. (1990). Pharmacokinetics and tissue penetration of fluoroquinolones.In Fluoroquinolones in the Treatment of Infectious Disease (Sanders, E. W. and Sanders, C. C., Eds), pp. 29-44. Physicians and Scientists Publishing Co, Glenview, IL.
62. Shimada, J. and Hori, S. (1992). Adverse effects of Quinolones. In Fluorinated Quinoiones—New Quinolone Antimicrobials (Mitsuhashi, S., Ed.). Progress in Drug Research, Vol. 38 (Junker, E., Ed.), pp. 133-44. Birkhauser Verlag, Basle.
63. Shimada, H. and Itoh, S. (1991). Effects of DU-6859 and the related quinolone antibacterial agents on mammalian chromosomes. In Program and Abstracts of the Thirty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1991. Abstract 1507. American Society for Microbiology, Washington, DC.
64. Shintani, S., Kusunoki, E. and Yamashita, S. (1991). Drug interactions of OPC-17116, a new quinolone antibacterial agent with nonsteroidal anti-inflammatory drugs in experimental animals. In Program and Abstracts Thirty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1991. Abstract 1479. American Society for Microbiology, Washington, DC.
65. Suto, M. J., Domagala, J. M., Roland, G. E., Mailloux, G. B. and Cohen, M. A. (1992). Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity. Journal of Medicinal Chemistry 35, 4745-50.
66. Takacs-Novak, K., Jozan, M., Hermecz, I. and Szasz, G. (1992). Lipophilicity of antibacterial fluoroquinolones. International Journal of Pharmaceutics 79, 89-96.
67. Talley, J. P. (1991). Fluoroquinolones-new miracle drugs? Postgraduate Medicine 89, 101-13.
68. Tsuji, A., Sato, H., Kume, Y., Tamai, I., Okezaki, E., Nagato, O. et al. (1988). Inhibitory effects of quinolone antibacterial agents on y-aminobutyric acid binding to receptor sites in rat brain membranes. Antimicrobial Agents and Chemotherapy 32, 190-4.
69. Wagai, N. and Tawara, K. (1992). Possible direct role of reactive oxygens in the cause of cutaneous phototoxicity induced by five quinolones in mice. Archives of Toxicology 66, 392-7.
70. Washington Drug Letter (1993). Mouse study irrelevant to Maxaquin says Searle. April 5, 3.
71. Wise, R., Andrews, J. M. and Brenwald, N. (1993). The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone. Journal of Antimicrobial Chemotherapy 31, 73-80.
72. Wolfson, J. S. and Hooper, D. C. (1989). Fluoroquinolone antimicrobial agents. Clinical Microbiology Reviews 2, 378-424.